ClinicalTrials.gg
RecruitingNCT07059975Updated Aug 24, 2026

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

An Early Phase 1 interventional study of Idarubicin Hydrochloride and Fludarabine in Acute Myeloid Leukemia and Pediatric AML, sponsored by Baylor College of Medicine. Recruiting at 1 site in United States. Open to participants aged 1 Month to 30 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Baylor College of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
1 Month to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing idarubicin in Leukemia, Myeloid, Acute — 10 open to participants now, 14 under way, 2 of them phase 3. Idarubicin · Leukemia, Myeloid, Acute.

Planned enrollment
42nd of 53
36 · median 61
Started
2025
with 1 other
Phase 1
13 of 55
2 open now
Primary completion
2028-10
later than 12 of 13 live
Registered
54th of 55
by date
Lead sponsor
1 of 55
Baylor College of Medicine

Among the 55 studies testing idarubicin in Leukemia, Myeloid, Acute, this one is the 42nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 in phase 1, reaches primary completion later than 12 of the 13 other live ones, and was the 54th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

10 of the 55 studies testing idarubicin in Leukemia, Myeloid, Acute are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About idarubicin

Idarubicin: first FDA approval 1990 (IDAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 1 Month to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing idarubicin in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at intermediate-risk (IR) and high-risk (HR) of relapse. The goal is to achieve similar or better survival with chemotherapy cycles that are intensive but less likely to cause long-term complications. Patients will enroll on this trial at the end of their first induction cycle.

The two cycles to be substituted are:

  • "Ida-FLA" (idarubicin+fludarabine/cytarabine) as Induction 2
  • "VIA" (venetoclax+idarubicin+cytarabine) as Intensification 1 of the HR treatment regimen, and Intensification 2 of the IR treatment backbone.

Researchers will evaluate side effects and outcomes for up to three years after enrollment.

Participants will also have the opportunity to participate in optional research studies including patient surveys and blood and bone marrow sample testing.

Read the detailed description

UPDATE AML is a research study that investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients at intermediate-risk (IR) and high-risk (HR) of the leukemia coming back ("relapse"). Newly diagnosed patients will receive standard Induction 1 treatment off study. If they do not have a FLT3-ITD mutation, they will be eligible to complete treatment on the UPDATE AML study. Patients considered Low Risk will receive the standard treatments outside of the UPDATE AML trial but will be eligible for the non-treatment parts of the trial. IR and HR patients will receive a combination of idarubicin, fludarabine, cytarabine (Ida-FLA) as their 2nd cycle of chemotherapy ("Induction 2"). This combination has shown desirable anti-leukemic activity in children whose leukemia has relapsed but has not yet been studied extensively in children newly diagnosed with AML. Secondly the trial will administer the new drug venetoclax (FDA approved for adults with AML but not for pediatric patients) combined with idarubicin and cytarabine as the 3rd or 4th cycle (of the HR or IR regimens respectively). Texas Children's Hospital will be providing the venetoclax.

The other major goal of UPDATE AML is to improve to detection of residual leukemia. Currently, the intensity of treatment for pediatric patients with AML depends on the genetic changes in the leukemia cells and their response to the first month of therapy. Of patients who have no detectable residual disease at the end of the first month, 30% of them will still relapse, indicating residual leukemia was still present, just not detected. Our study will develop individualized tests for each patient's genetic change which should increase detection of tiny amounts of residual leukemia. If our trial can successfully develop these individualized tests, future pediatric AML trials will incorporate these tests into use for all patients.

The research study procedures include screening for eligibility study treatment, evaluation, administration of the substituted chemotherapy cycles, and follow-up visits. Participants will be offered the possibility to provide additional blood and bone marrow samples (to be collected only at times of regular medical examination). There are additional surveys patients and parents can participate in, to understand the challenges facing families undergoing pediatric AML treatment.

Besides the 2 substituted chemotherapy cycles, patients will otherwise receive standard chemotherapy as their relapse risk indicates. Patients will be followed for approximately 3 years from enrollment.

It is expected that about 36 people will take part in this research study.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Pediatric AML

Keywords

  • venetoclax
  • measurable residual disease (MRD)
  • digital PCR
04

Who can participate

Ages eligible
1 Month to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age Patients ≥ 1 months old to ≤ 30 years old are eligible

Patients must be diagnosed with AML or myeloid sarcoma according to the 2022 WHO classification with or without extramedullary disease. Patients with AML must have 1 of the following at initial diagnosis:

- Diagnosis

  1. ≥ 20% bone marrow blasts

    • In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core .
  2. \< 20% bone marrow blasts with one or more of the genetic abnormalities below:

    • t(8;21)(q22;q22.1) RUNX1::RUNX1T1
    • inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBFB::MYH11
    • Translocation involving 11q23.3 KMT2A rearrangement
    • t(6;9)(p23;q34.1) DEK::NUP214
    • inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) MECOM rearrangement
    • Megakaryoblastic with t(1;22)(p13.3;q13.3) RBM15::MRTFA
    • Mutated NPM1
    • CEBPA bZIP mutation
    • t(1;22)(p13.3;q13.1) RBM15(OTT) fusion
    • t(7;12)(q36.3;p13.2) MNX1::ETV6
    • t(8;16)(p11.2;p13.3) KAT6A::CREBBP - t(5;11)(q35.3;p15.5) NUP98::NSD1
    • inv(16)(p13.3q24.3) CBFA2T3::GLIS2
    • t(11;12)(p15.5;p13.5) NUP98::KDM5A
    • 11q23.3 partial tandem duplication (PTD) KMT2A PTD
  3. A complete blood count (CBC) documenting the presence of at least 1,000/µL circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (i.e., a WBC count ≥ 10,000/μL with ≥ 10% blasts or a WBC count of ≥ 5,000/μL with ≥ 20% blasts).
  4. Biopsy-proven myeloid sarcoma with or without bone marrow involvement.

    Note: patients with newly diagnosed AML, myelodysplasia-related (that are not from conditions listed in protocol section 4.2.1) ARE eligible while patients with therapy-related AML are excluded.

    - Prior Therapy Patients must receive DA10+GO (Cytarabine days 1-10 + Daunorubicin days 1,3,5 [DA10] + Gemtuzumab ozogamcin [GO]) as prescribed in AAML1831 or the TXCH practice standard for Induction 1. Patients may have received any number of intrathecal treatments and have any CNS status at the time of enrollment.

    • Performance Status Patients must have a performance status corresponding to /Lansky score >/=40. (Use Karnofsky for patients ≥16 years of age and Lanksy for patients \<16 years of age.)
    • Organ Function Requirements All laboratory studies to determine eligibility must be performed within seven (7) days prior to enrollment unless otherwise indicated. Laboratory values used to assess eligibility must be no older than 7 days at the start of Induction 2 therapy and need not be repeated if therapy starts within 7 days of the eligibility labs. If a post-enrollment lab value is outside the limits of eligibility, or laboratory values are >7 days old, then the following laboratory evaluations must be re-checked within 48 hours prior to initiating therapy: , (SGPT) and serum creatinine. If the recheck is outside the limits of eligibility, the patient should be followed with periodic labs but may not receive protocol therapy until the bilirubin, ALT, and/or serum creatinine meet eligibility criteria. If >14 days have passed from the planned start of protocol therapy and the bilirubin, ALT, and/or serum creatinine are still outside the limits of eligibility, the patient may not receive protocol therapy and rather will be considered a screen failure.

    Adequate renal function defined as:

    • An estimated or ≥ 60 ml/min/1.73m2. Any calculation method is acceptable, including the automatic creatinine clearance provided within the Epic EMR.

    Adequate liver function defined as:

    • A direct bilirubin \< 2 mg/dL
    • ALT \<5x or 225 U/L, with the ULN being 45 U/L for the purpose of this study.

    Adequate coagulation defined as:

    • ≤ 1.5

    Adequate cardiac function defined as:

    • (EF) ≥ 50% (preferred method Biplane Simpson's EF) or if EF unavailable, shortening fraction (SF) ≥ 24%, within 14 days prior to planned start of Induction 2 therapy.
    • For patients with cardiac dysfunction (EF \< 50% or SF \<24% if EF is unavailable) prior to enrollment, if clinically safe and feasible, repeat echocardiogram is strongly advised in order to confirm cardiac dysfunction following clinical stabilization, particularly if occurring in the setting of sepsis or other transient physiologic stressor. If the repeat echocardiogram demonstrates an EF ≥ 50%, the patient is eligible to enroll.

      • All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Patients with the following constitutional conditions are not eligible:

    • Fanconi anemia
    • Schwachman Diamond Syndrome
    • Telomere Disorders
    • Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21
    • Germline predispositions known, or suspected by the treating physician, to increase risk of toxicity with AML therapy
    • Therapy-related AML
  • Patients with any of the following oncologic diagnoses are not eligible:

    • Any concurrent
    • Juvenile myelomonocytic leukemia
    • Philadelphia chromosome positive AML
    • Mixed phenotype acute leukemia
    • Acute promyelocytic leukemia
    • AML with FLT3 internal tandem duplication (FLT3-ITD) allelic ratio >0.1
  • Pregnancy and Breastfeeding • Female patients who are pregnant may not participate. A pregnancy test is required for female patients of .

    • Lactating females who plan to breastfeed their infants are not eligible.
    • Sexually active patients of who have not agreed to use an effective method for the duration of their study participation are not eligible.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Intermediate Risk (IR) AML

    Patients will receive Ida-FLA as Induction 2, cytarabine/etoposide ("AE") as Intensification 1, VIA as Intensification 2, and Capizzi AraC as intensification 3.

    Drug: Idarubicin Hydrochloride · Drug: Fludarabine · Drug: Cytarabine (Ara-C) · Drug: Venetoclax · Drug: Etoposide · Drug: Asparaginase Erwinia Chrysanthemi (recombinant) · Drug: Intrathecal triple

  • Experimental
    High risk (HR) AML

    Patients will receive Ida-FLA as Induction 2 and VIA as Intensification 1. These patients will then proceed on to a hematopoietic stem cell transplantation if an appropriate donor is found, otherwise will receive 2 more cycles of chemotherapy following the IR regimen.

    Drug: Idarubicin Hydrochloride · Drug: Fludarabine · Drug: Cytarabine (Ara-C) · Drug: Venetoclax · Drug: Intrathecal triple

  • Other
    Low risk (LR)

    Low risk pediatric AML patients will receive standard of care chemotherapy but have the option to participate in correlative studies

    Other: SOC

Interventions

  • DrugIdarubicinStudies of IdarubicinIdarubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Idarubicin is given in combination with fludarabine and cytarabine for Ida-FLA, and in combination with venetoclax and cytarabine for VIA.

  • Fludarabine is given in combination with idarubicin and cytarabine for Ida-FLA.

  • DrugCytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cytarabine is given in combination with other chemotherapy agents in every cycle and both arms.

  • Venetoclax is given in combination with idarubicin and cytarabine for VIA.

  • Etoposide is given in combination with cytarabine for AE, as Intensification 1 for IR patients.

  • DrugAsparaginase erwinia chrysanthemiStudies of Asparaginase erwinia chrysanthemiAsparaginase erwinia chrysanthemi pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rylaze is given in combination with cytarabine for Intensification 3 for IR patients.

  • DrugIntrathecal triple

    Methotrexate, hydrocortisone and cytarabine are combined into one preparation for intrathecal administration at multiple time points during treatment.

  • OtherSOC

    Low-Risk Patients will receive Texas childern's Hospital practice standard for de novo AML.

06

What researchers measure

Primary outcomes

  1. Tolerability rate of Ida-FLA

    Tolerability rate is the proportion of participants in the tolerability dataset who did not experience an intolerable event during Induction 2 for IR and HR patients. Number of intolerable participants will be used. Intolerability is defined by events outlined in Section 6.6 of the protocol as follow: Non-Hematological Toxicity: Any Grade 5 toxicity, Grade 4 left ventricular systolic dysfunction or QTc prolongation, Grade 4 infection or sepsis, or other Grade 4+ non-hematologic toxicity except: * Grade 4 nausea/vomiting (\<3 days) * Grade 4 ALT/AST/GGT elevation (returns to ≤Grade 1 before next cycle) * Grade 4 electrolyte abnormalities (corrected by supplementation) * Cycle delays \>50 days indicate intolerability. Hematologic Toxicity: Intolerability includes failure to recover ANC \>500/mL and platelets \>20,000/mL (without transfusion in past 7 days) by day 50 or cycle start delay \>50 days. A cycle of Ida-FLA is 29-36 days.

    Time frame: From Day 1 of Ida-FLA through up to 50 days after completion of Ida-FLA

  2. Tolerability rate of VIA for IR patients

    Tolerability rate is the proportion of participants in the tolerability dataset who did not experience an intolerable event during intensification 2 for IR patients as the 4th cycle. Number of intolerable participants will be used. Intolerability is defined by events outlined in Section 6.6 of the protocol as follow: Non-Hematological Toxicity: Any Grade 5 toxicity, Grade 4 left ventricular systolic dysfunction or QTc prolongation, Grade 4 infection, or other Grade 4+ non-hematologic toxicity except: * Grade 4 nausea/vomiting (\<3 days) * Grade 4 ALT/AST/GGT elevation (returns to ≤Grade 1 before next cycle) * Grade 4 electrolyte abnormalities (corrected by supplementation) * Cycle delays \>50 days indicate intolerability. Hematologic Toxicity: Intolerability includes failure to recover ANC \>500/mL and platelets \>20,000/mL (without transfusion in past 7 days) by day 50 or cycle start delay \>50 days. A cycle of VIA is 29-36 days.

    Time frame: From Day 1 of VIA through up to 50 days after completion of VIA

  3. Tolerability rate of VIA for HR patients

    Tolerability rate is the proportion of participants in the tolerability dataset who did not experience an intolerable event during intensification 2 for HR patients as the 3rd cycle. Number of intolerable participants will be used. Intolerability is defined by events outlined in Section 6.6 of the protocol as follow: Non-Hematological Toxicity: Any Grade 5 toxicity, Grade 4 left ventricular systolic dysfunction or QTc prolongation, Grade 4 infection, or other Grade 4+ non-hematologic toxicity except: * Grade 4 nausea/vomiting (\<3 days) * Grade 4 ALT/AST/GGT elevation (returns to ≤Grade 1 before next cycle) * Grade 4 electrolyte abnormalities (corrected by supplementation) * Cycle delays \>50 days indicate intolerability. Hematologic Toxicity: Intolerability includes failure to recover ANC \>500/mL and platelets \>20,000/mL (without transfusion in past 7 days) by day 50 or cycle start delay \>50 days. A cycle of VIA is 29-36 days.

    Time frame: From Day 1 of VIA through up to 50 days after completion of VIA

Secondary outcomes

  1. Complete remission rate

    Complete remission (CR/CRi/CRp) will be defined asbone marrow blast \<5% by morphology with regenerating normal hematopoietic cells, negative CSF cytology, and no extramedullary disease. Number of complete remission respondents.The complete remission rate will be estimated as the proportion of the Induction 2 population that is in complete remission at the end of Induction 2 for IR and HR patients A cycle of Ida-FLA(induction 2) is 29-36 days.

    Time frame: at the end of Induction 2 which may occur between day 29 and day 36 of the cycle

  2. MRD negative rate

    The MRD assessment will be based on the subset of the Induction 2 in IR + HR population that were MRD positive at the end of Induction 1.The MRD negative rate will be estimated as the proportion of IR+HR patients who are MRD negative (\<0.05% by flow cytometry) at the end of Induction 2, out of the number of IR+HR patients who were MRD positive (\>0.05% by flow cytometry) at the end of Induction 1. A cycle of Ida-FLA(induction 2) is 29-36 days.

    Time frame: at the end of Induction 2 which may occur between day 29 and day 36 of the cycle

  3. 3 year event-free survival

    Event-free survival (EFS) is defined as the time from study enrollment until refractory disease or relapse, death due to any cause or last date of follow-up over 3 years in IR and HR, separately. The median survival time will be estimated using the Kaplan-Meier method.

    Time frame: from enrollment up to 3 years

  4. 3 year overall survival

    Overall survival (OS) is defined as time from study entry until death due to any cause or last date of follow-up over 3 years in IR and HR, separately.The median survival time will be estimated using the Kaplan-Meier method.

    Time frame: From enrollment up to 3 years

  5. Rate of count recovery in IR Intensification 1

    The time to post-nadir recovery of absolute neutrophil count (ANC) to \>500/μL and platelets to \>20,000/μL (without transfusion) is determined for IR patients at the end of Intensification 1. Count recovery is defined above. Day 42 is a standard benchmark for count recovery, beyond which recovery is considered delayed. The proportion of IR patients who achieve full count recovery by day 42 of Intensification 1 will be estimated using the Kaplan-Meier method. A cycle of intensification 1 is 29-36 days.

    Time frame: at the end of Intensification 1 which may occur between day 29 and day 36 of the cycle

  6. Tolerability rate of intensified regimen as a whole for IR patients

    Tolerability of the IR regimen overall is assessed at the end of Intensification 3 for IR patients. The overall tolerability rate for IR patients receiving the intensified IR regimen as a whole will be calculated as the proportion of IR patients who complete of protocol therapy without severe toxicity requiring removal from the regimen, as defined in Section 6.6 of the protocol as follow: Non-Hematological Toxicity: Any Grade 5 toxicity, Grade 4 cardiac disorder, Grade 4 infection, or other Grade 4+ non-hematologic toxicity except: * Grade 4 nausea/vomiting (\<3 days) * Grade 4 ALT/AST/GGT elevation (returns to ≤Grade 1 before next cycle) * Grade 4 electrolyte abnormalities (corrected by supplementation) * Cycle delays \>50 days indicate intolerability. Hematologic Toxicity: Intolerability includes failure to recover ANC \>500/mL and platelets \>20,000/mL (without transfusion in past 7 days) by day 50 or cycle start delay \>50 days. A cycle of intensification 3 is 29-36 days.

    Time frame: at the end of Intensification 3 which may occur between day 29 and day 36 of the cycle

  7. Tolerability rate of intensified regimen as a whole for HR patients

    Tolerability of the HR regimen overall is assessed at day +30 after HSCT for HR patients. The overall tolerability rate for HR patients receiving the intensified HR regimen as a whole will be calculated as the proportion of HR patients who complete of protocol therapy and HSCT without severe toxicity requiring removal from the regimen, as defined in Section 6.6 of the protocol as follow: Non-Hematological Toxicity: Any Grade 5 toxicity, Grade 4 cardiac disorder, Grade 4 infection, or other Grade 4+ non-hematologic toxicity except: * Grade 4 nausea/vomiting (\<3 days) * Grade 4 ALT/AST/GGT elevation (returns to ≤Grade 1 before next cycle) * Grade 4 electrolyte abnormalities (corrected by supplementation) * Cycle delays \>50 days indicate intolerability. Hematologic Toxicity: Intolerability includes failure to recover ANC \>500/mL and platelets \>20,000/mL (without transfusion in past 7 days) by day 50 or cycle start delay \>50 days.. A cycle is 29-36 days.

    Time frame: at day 30 after completion of HSCT

07

Study locations

1 of 1 sites recruiting
  • Texas Children's Cancer and Hematology Center
    Houston, Texas 77030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — All of the planned analyses, including the correlative biology, will be done by members of the study committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 36 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jul 11, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Aug 2031
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07059975
Responsible party
Joanna Yi (Associate Professor, Baylor College of Medicine) — Principal investigator
First posted
Jul 11, 2025
Start date
Oct 22, 2025
Primary completion
Oct 2028 (estimated)
Completion
Aug 2031 (estimated)
Last update
Aug 24, 2026

Study contacts

Joanna S Yi, MD
Contact
jsyi@texaschildrens.org
832-824-6699
Alexandra M Stevens, MD, PhD
Contact
amsteven@texaschildrens.org
832-824-4824

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Idarubicin · Fludarabine · Cytarabine · Venetoclax · Etoposide · Asparaginase erwinia chrysanthemi

Start the discussion